Overcoming obstacles in digital medicine

MedCity News

A panel discussion on the future of digital medicine highlighted some of the collaborations taking place between pharma companies and digital health, as well as some of the challenges facing the push towards mainstream implementation.

Is digital the future of medicine?

World of DTC Marketing

Digital medicine has been thrust into the spotlight because of the pandemic and the media hype is in overdrive. A study of some 16m American ones just reported in jama Internal Medicine , a journal, found that their use of telemedicine surged 30-fold between January and June.

From Persia To Precision Medicine

PharmExec

In episode 117, Helen Sabzevari, CEO of Precigen, discusses her drive to study science as a Persian-born woman, the opportunities she’s had to research immunology, and how she’s now developing next-generation CAR-T treatments for cancer, in addition to other therapies.

From Persia To Precision Medicine

Pharma Leaders

In episode 117, Helen Sabzevari, CEO of Precigen, discusses her drive to study science as a Persian-born woman, the opportunities she’s had to research immunology, and how she’s now developing next-generation CAR-T treatments for cancer, in addition to other therapies. Compliance Channel Posts

Real-word health data firm launches with backing from WashU Medicine, BJC HealthCare

MedCity News

Health data company CuriMeta launched on Tuesday and announced the close of a $6 million seed funding round led by its two institutional partners, BJC HealthCare and the Washington University School of Medicine.

FDA Publishes Guidance on Regenerative Medicine Therapies

PharmaTech

The new draft guidance describes a standards recognition program for regenerative medicine therapies.

The Silver Lining Of Innovation in Genetic Medicine

PharmExec

Failed efforts do not overshadow field’s progress, resolve.

Penn Medicine’s venture fund makes 2 investments to address SDOH

MedCity News

The Penn Medicine-Wharton Fund for Health, Penn’s venture fund focused on social determinants of health, recently announced investments in its fifth and sixth companies.

EMA human medicines committee (CHMP) highlights, September 2022

European Pharmaceutical Review

Biosimilar medicine Ximluci (ranibizumab) for the treatment of neovascular age-related macular degeneration, a progressive retinal macular disease, causing gradual vision impairment, mainly in the elderly population. 11 medicines for indication extension.

How does irradiation sterilisation impact herbal medicines?

European Pharmaceutical Review

In order to meet microbiological quality standards, herbal medicine pills are often irradiated at the primary package or final product stage. Pills are a popular formulation of herbal medicines, such as Traditional Chinese medicine (TCM) or Kampo medicine from China or Japan.

Blueprint Medicines announces financing partnerships for $1.25bn

Pharmaceutical Technology

Blueprint Medicines has entered strategic financing partnerships for up to $1.25bn with life sciences-focused investors Sixth Street and Royalty Pharma. The post Blueprint Medicines announces financing partnerships for $1.25bn appeared first on Pharmaceutical Technology.

Proteomics Keys Promise Of Predictive Medicine

PharmExec

Major stakeholders—including policymakers, public-private interests, and academia—are increasingly embracing the potential of proteomics technology in reshaping diagnostics and patient care.

EMA Publishes Guidance on Preventing Medicine Shortages

PharmaTech

The European Medicines Agency guidance highlights key principles and examples of good practices to prevent and manage shortages of human medicines.

Sanofi makes low-cost medicines pledge for low-income countries

Pharma Phorum

Sanofi has said it will make 30 of its most commonly prescribed medicines available at non-profit prices to 40 lower-income countries, as part of a global health initiative launched by the company last year.

Gemini enters business combination deal with Disc Medicine

Pharmaceutical Technology

Gemini Therapeutics has signed a definitive agreement to merge with Disc Medicine in an all-stock deal to create a clinical-stage biopharmaceutical company. The merged company is expected to be named Disc Medicine, which will have corporate headquarters in Watertown, Massachusetts, US.

Narrative Medicine: What is it and how can it help me?

InCrowd

How can this narrative be a form of medicine? Columbia University describes narrative medicine as “an interdisciplinary field that brings powerful narrative skills of radical listening and creativity from the humanities and the arts to address the needs of all who seek and deliver health care.

Senda raises funds to advance programmable medicines platform development

Pharma Leaders

The post Senda raises funds to advance programmable medicines platform development appeared first on Pharmaceutical Business review.

Obesity represents a catastrophic failure of government policy, public health, and medicine

World of DTC Marketing

The post Obesity represents a catastrophic failure of government policy, public health, and medicine. SUMMARY: Obesity has many causes, and while we would like to think the answer is as easy as people exercising more and eating less, it isn’t that simple.

FDA accepts for priority review Seagen’s sNDA for colorectal cancer medicine

Pharma Leaders

The post FDA accepts for priority review Seagen’s sNDA for colorectal cancer medicine appeared first on Pharmaceutical Business review.

NHS England trials first medicine deliveries by drone

Pharma Phorum

Using drones will cut the transit time for the medicines from four hours to 30 minutes, and will also require less fuel – an increasingly important consideration as prices rocket at petrol pumps. The post NHS England trials first medicine deliveries by drone appeared first on.

Transpire Bio signs with Recipharm for inhaled medicine development

European Pharmaceutical Review

Transpire Bio and Recipharm have signed a definitive agreement for the development of TRB-1 and TRB-2 – two inhaled medicines for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). We are very excited to be working with Recipharm to advance these important medicines.”.

Sanofi unveils global health brand for medicines supply

Pharmaceutical Technology

Through the Impact brand, which comprises insulin, glibenclamide and oxaliplatin among others, the company will supply its 30 medicines in 40 lower-income countries in the world. The post Sanofi unveils global health brand for medicines supply appeared first on Pharmaceutical Technology.

Aurigene Pharmaceutical Services Limited-Walk-In Drive for R&D Medicinal Chemistry On 11th Sept’ 2022

Pharma Pathway

Aurigene Pharmaceutical Services Limited-Walk-In Drive for R&D Medicinal Chemistry On 11th Sept’ 2022. Aurigene Pharmaceutical Services Limited-Walk-In Drive for R&D Medicinal Chemistry On 11th Sept’ 2022 @ Hyderabad & Bangalore. Aurigene Pharmaceutical Services Limited-Walk-In Drive for R&D Medicinal Chemistry On 11th Sept’ 2022. Job Description.

Sangamo’s cell therapy receives EC orphan medicinal product designation

Pharmaceutical Technology

Sangamo Therapeutics has received orphan medicinal product designation (OMPD) from the European Commission (EC) for its Investigational autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy, TX200, for solid organ transplantation.

Sanofi launches Impact® brand of medicines for low-income countries

European Pharmaceutical Review

The Impact ® brand includes 30 Sanofi medicines and covers a wide range of therapeutic areas, including diabetes, cardiovascular disease, tuberculosis, malaria and cancer. Medicines include insulin, glibenclamide and oxaliplatin, the company said.

Health Care Providers Should Counsel Patients on Integrative Medicine Strategies

Pharmacy Times

Study suggests that health care providers should discuss with patients whether they are using any integrative medicine strategies, which ones, and why.

Science & Medicine Group Expands as Commercial Data Insights Leader with Amplion Acquisition

PharmExec

The integration of the "Amplion knowledgebase" and next-generation data architecture will immediately expand Science & Medicine Group's capabilities to deliver more comprehensive, actionable insights to commercial organizations at life science equipment and reagent manufacturers as well as pharmaceutical services providers. us

Reproductive healthcare is under attack. Precision medicine is more important than ever

MedCity News

The need for precision medicine in the reproductive health care sphere has never been greater: for much of the country, the risks of unwanted pregnancy are exacerbated by abortion legislation and unscientific political rhetoric around birth control.

How these parents of a child with a rare disease are making precision medicine work for them – the pharmaphorum podcast

Pharma Phorum

Lucy’s story shows how the promise of precision medicine doesn’t always line up with the profit motive and economies of scale in the healthcare industry. Patients Podcast R&D Video Views & Analysis Views and analysis Moonshots for Unicorns PGAP3-CDG precision medicine Rare diseases

Cell and gene therapies: why advanced medicines call for specialised logistics

Pharmaceutical Technology

But scientists have struggled to find effective treatments for many of these diseases since the dawn of modern medicine. It is certainly a pivotal moment for the cell and gene industry, with the next decade of R&D and clinical trials expected to transform the future of medicine.

CCC Now Offering Subscriptions to the JAMA Network and The New England Journal of Medicine Through RightFind

Copyright Clearance Center

The JAMA Network brings JAMA together with JAMA Network Open and 11 specialty medical journals to offer enhanced access to the research, reviews, and opinions shaping the future of medicine. August 9, 20 22 – Danvers, Mass. –

How can evidence-based medicine (EBM) methodology support drug withdrawals?

European Pharmaceutical Review

Our research paper, which is being submitted for publication this summer, aims to create an evidence-based medicine (EBM) methodology that can assess this positive impact, to further help regulators determine appropriate risk minimisation measures. ketoconazole – an antifungal medicine.

Milestones and Momentum: Assessing Advancements in Personalized Medicine

PharmExec

The road to precision medicine as a fixture in healthcare delivery is still a journey, but recent advances and new understandings in gene profiling, biomarker development, and AI and data analytics are steadily bringing these therapies closer to the individual patient every day.

Securing every dose with an edible security technology for safe medicines

European Pharmaceutical Review

FAKE MEDICINES are not a new problem, and pose a tremendous threat to patient safety and public health in society regardless of a country’s economic status. Some, 250,000 child deaths per year can be attributed to counterfeit malaria and pneumonia medicines. Counterfeit medicines.

ViiV Healthcare, Medicines Patent Pool partner to expand HIV drug access

Pharma Leaders

This licence enables the least developed, low-income, lower middle-income as well as Sub-Saharan African countries to access the long-acting HIV prevention medicine.

MHRA to Play Greater Role in International Medicines Regulation

PharmaTech

MHRA has been accepted as a full member of three international work-sharing partnerships aimed at making sure medicines and medical devices are regulated safely and efficiently across the world.

Homeopathic Pharmacy: A Natural Alternative to Modern Medicine

Teachntest

Homeopathic Pharmacy: A Natural Alternative to Modern Medicine. With the rise in technological innovation and the push towards a more Westernized lifestyle, we’ve begun to forget about the natural remedies that our ancestors relied on for centuries.

Mesh Bio, MultiOmic partner to develop chronic metabolic disease medicines

Pharma Leaders

The post Mesh Bio, MultiOmic partner to develop chronic metabolic disease medicines appeared first on Pharmaceutical Business review. As part of the collaboration, the companies will carry out an observational study in chronic metabolic disease patients as well as those with increased risk of complications like. Industry News

Flagship Pioneering’s Senda Bio secures $123M for new ‘programmable medicines’

MedCity News

Biotech startup Senda Biosciences is developing technology that yields a new type of medicine with two programming components: one directs the therapy to go to a particular destination in the body while the second tells the therapy what to do once it gets there.

Putting an End to the Opioid Epidemic in Emergency Medicine

Pharmacy Times

What we're seeing as a trend is this significant increase in synthetic opioids, specifically fentanyl, being contaminated and causing severe overdoses.